ReviewJournal of fungi (Basel, Switzerland)2023
Onychomycosis: Old and New.
Review in Journal of fungi (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06971341 (Retrospective Observational Study in Patients With Onychomycosis Treated With Mycoclear® and Ciclopirox), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retrospective Observational Study in Patients With Onychomycosis Treated With Mycoclear® and Ciclopirox
Who cites it
31 citing papers in PubMed, 67 citations in OpenAlex.
- Trial
- Comparative evaluation of conventional and nanopore approaches in onychomycosis diagnosis.Diagnostic microbiology and infectious disease · 2026Article
- Distal Nail Canal Visible on Onychoscopy as a Diagnostic Sign of Dermatophytoma.Dermatology practical & conceptual · 2026Article
- Cutaneous-Tropism Viruses: Unraveling Pathogenetic Mechanisms and Immunoprophylactic Strategies.Life (Basel, Switzerland) · 2026Review
- Artificial Intelligence Meets Nail Diagnostics: Emerging Image-Based Sensing Platforms for Non-Invasive Disease Detection.Bioengineering (Basel, Switzerland) · 2026Review
- Diagnostic accuracy of fluorescence microscopy of hematoxylin-eosin-stained nail sections for onychomycosis.Frontiers in medicine · 2026Article
- Application of artificial intelligence in geriatric infection: recent advances and prospects.Frontiers in cellular and infection microbiology · 2026Review
- Infrared Spectroscopy as a Promising Tool for Diagnosing and Typing Human Pathogenic Fungi.Mycoses · 2026Review
- Article
- Dermatophyte-Selective Imidazole-Thiosemicarbazides: Potent In Vitro Activity AgainstInternational journal of molecular sciences · 2025Article
- Nanocarriers in Ungual Drug Delivery.Pharmaceutics · 2025Review
- A Comprehensive Review on the Valorization of Bioactives from Marine Animal By-Products for Health-Promoting, Biofunctional Cosmetics.Marine drugs · 2025Review
- An Assessment of the Antifungal Efficacy of a Novel Topical Onychomycosis Treatment Using Human Nail and Skin Infection Models.Journal of fungi (Basel, Switzerland) · 2025Article
- Use of a 3D Model with Reconstructed Human Epidermis Infected with Fungi and Covered with a Bovine Nail to Simulate Onychomycosis and to Evaluate the Effects of Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2025Article
- Review
- Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.RSC advances · 2025Review
- A case report of childhood onychomycosis caused by the rare yeastMedical mycology case reports · 2025Article
- Analysis of Causative Factors and Potential Predictors of Onychomycosis: A Retrospective Single-Center Study in Poland.Journal of fungi (Basel, Switzerland) · 2025Article
- Novel Therapeutic Approaches Emerging in the Field of Onychomycosis.Recent advances in anti-infective drug discovery · 2025Review
- Kerion-like lesions following an autoinoculation event in patient with chronic onychomycosis - Case report.Medical mycology case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Onychomycosis is a common chronic fungal infection of the nail that causes discoloration and/or thickening of the nail plate. Oral agents are generally preferred, except in the case of mild toenail infection limited to the distal nail plate. Terbinafine and itraconazole are the only approved oral therapies, and fluconazole is commonly utilized off-label. Cure rates with these therapies are limited, and resistance to terbinafine is starting to develop worldwide. In this review, we aim to review current oral treatment options for onychomycosis, as well as novel oral drugs that may have promising results in the treatment of onychomycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.